Point of View

A Case for Pharmacogenomics in Management of Cardiac Arrhythmias

Gaurav Kandoi¹, Anjali Nanda², Vinod Scaria³, Sridhar Sivasubbu⁴

¹Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Main Bawana Road, Delhi, India.
²International Institute of Health Management Research, Plot no. 3, Sector 18A, Phase-II, Dwarka, New Delhi - 110075.
³GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Mall Road, Delhi 100 007, India.
⁴Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Mall Road, Delhi 100 007, India.

Address for Correspondence: Dr. Vinod Scaria, GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Mall Road, Delhi 100 007, India. E-mail: vinods/at/igib.res.in

Financial Support: CSIR India.

Conflict of Interest: None.

Abstract

Disorders of the cardiac rhythm are quite prevalent in clinical practice. Though the variability in drug response between individuals has been extensively studied, this information has not been widely used in clinical practice. Rapid advances in the field of pharmacogenomics have provided us with crucial insights on inter-individual genetic variability and its impact on drug metabolism and action. Technologies for faster and cheaper genetic testing and even personal genome sequencing would enable clinicians to optimize prescription based on the genetic makeup of the individual, which would open up new avenues in the area of personalized medicine. We have systematically looked at literature evidence on pharmacogenomics markers for anti-arrhythmic agents from the OpenPGx consortium collection and reason the applicability of genetics in the management of arrhythmia. We also discuss potential issues that need to be resolved before personalized pharmacogenomics becomes a reality in regular clinical practice.

Keywords: Arrhythmia, Pharmacogenomics, Personal genome, Genetic testing, Adverse drug reactions

Arrhythmias or disorders of the cardiac rhythm are not uncommon in clinical settings and one of the major causes of mortality and morbidity. Atrial Fibrillation is supposed to be rare in young healthy individuals unless without underlying cardiac pathology [1], while prevalent in the elderly and affects roughly around 2-5 Million individuals in the United States alone [2]. Ventricular fibrillation has a smaller incidence of close to 0.4 million [3]. Ventricular tachyarrhythmias contribute significantly to the morbidity and mortality in patients with underlying
coronary artery disease. It has been estimated that close to a half of deaths due to coronary artery disease is caused by ventricular arrhythmias [4]. Apart from the genetic and underlying cardiac disease as causes of cardiac rhythm abnormalities, a number of therapeutic agents, including drugs not directly used in the therapy of cardiac rhythm abnormalities have now been implicated to cause significant prolongation of QT interval and a form of ventricular arrhythmia, torsades de pointes, which is potentially fatal [5]. Recent reports also point to cardiac arrhythmias as one of the top causes for drug withdrawal and failure of clinical trials [6].

No major study on the incidence of arrhythmias or adverse drug reactions to anti-arrhythmic drugs throughout India has been performed. The lack of adequate epidemiological data in this important area has been highlighted in recent publications [4]. According to a report of arrhythmia care in India, published in 2002, the prevalence of patients with arrhythmias in the country is around 2 million [7]. Studies have also pointed to the high prevalence of asymptomatic arrhythmias in elderly patients [8]. According to the reports from the National pharmacovigilance programme, several cases of adverse drug reactions to anti-arrhythmic agents have been reported from people across India. Verapamil and Amiodarone have been reported to cause Steven Johnsons syndrome. Atenolol has been similarly reported to have adverse drug events like fatigue, cough and edema in a study conducted in South India [9]. Similar studies have shown Atenolol to be associated with around 4-5% of total adverse drug reactions reported.

Individuals vary widely in their response to therapeutic agents, and a large component of this variability is modulated through the genetic makeup of the individual. Apart from the variability in response, genetic variations are also now known to contribute significantly to Adverse Drug Reactions (ADRs). One of the earliest contributions to understanding of genomics of external agents have stemmed from the observations of the British physician Garrod, who proposed that defects in enzymatic pathways in unusual diseases of metabolism could produce unusual sensitivity to chemical agents. Molecular genetic dissection of congenital conditions in humans has contributed immensely to the overall understanding of the genetics of heart rhythm. The field has now grown by leaps and bounds with the advent of modern tools and techniques, which enables dissecting genetic phenomena at single base-pair resolution. The advent of genomics technologies has paved the way to deciphering the molecular genetic mechanisms of variability in response to therapeutic agents. This variability could be caused by genetic variations, which modulate the pharmacokinetics or pharmacodynamics of the drug. This could involve variations in genes involved in drug transport/metabolism right up to variations in drug-targets and off-targets. The field of understanding genetic variability in the response to drugs has now emerged into a full-fledged branch of biology - pharmacogenomics with the potential to significantly improve disease management. The field has also offered novel clues towards understanding mechanisms and pathways, which involves therapeutic agents.

The last couple of decades have seen enormous improvements in the management of cardiac arrhythmias. Due to limited benefits and safety related concerns, very few drugs have been successful and have been commonly used in the treatment of arrhythmias. The field has also seen the emergence of newer classes of drugs which function by normalizing the channel activity rather than blocking them. According to the popular Singh Vaughan Williams classification schema, drugs are placed based on the mechanism of action. The classification scheme has improved over time, presently including the miscellaneous class, which includes drugs which could not fit any of the previous classes. Recent years have seen a number of publications detailing the pharmacogenomics of anti-arrhythmic drugs [10-13]. Though many classes of anti-arrhythmic agents are not particularly used anymore currently in regular clinical practice except in special settings, the wealth of information on pharmacogenomics encompasses the commonly used classes of drugs as well. The Drugs and the genes involved
in the pharmacogenomics of anti-arrhythmics and the respective references are summarized in Table 1 [14-77].

Table 1. Summary of drugs, genes involved in the pharmacogenomics of anti-arrhythmic drugs.

| Class of Drug | Drug Name | Genes with Pharmacogenomic markers | References |
|---------------|-----------|-----------------------------------|------------|
| Class 1a      | Quinidine | SCN5A                             | 14         |
| Class 1b      | Lidocaine | SCN5A, SCN9A, SCN4A               | 15-17      |
| Class 1b      | Phenytion | CYP2C9, CYP2C19, HLA-B, HLA-DR, HLA-C, EPHX1, SCN2A, SCN1A, ABCB1 | 18-26      |
| Class 2       | Atenolol  | CACNA1C, GRK5, ADRB1, ADRB2, LDLR, APOB, EDN1, GNB3, GNAS, TGFBR1, AGT, ACE, CYP11B2, AGTR1, ALAP | 27-45      |
| Class 2       | Carvedilol| ADRB1, ADRB2                      | 46-53      |
| Class 3       | Metoprolol| ADRB1, GRK5, GRK4, CYP2D6, ADRB2  | 47, 49, 52, 54-63 |
| Class 3       | Amiodarone| KCNH2                             | 64         |
| Class 3       | Dofetilide| KCNH2                             | 65         |
| Class 4       | Verapamil | CACNB2, CACNA1C, NOS1AP, ADRB1, ADRB2, KCNMB1, KCNH2 | 27, 30, 66-69 |
| Class 5       | Digoxin   | ABCB1                             | 70-77      |

Realizing the dream of personalized medicine is not without challenges and focused intervention. The major challenge in understanding the intricacies of genomic variations and deciphering the potential effects on pharmacokinetics and pharmacodynamics is the lack of comprehensive models of drug metabolism and action for many drugs. Understanding and charting drug pathways is the first step towards this dream. A systems level understanding of the drug pathways would enable us to overlay genomic variations and offer smart guesses on drugs that could be involved. The drug pathways for many drugs are complicated, involving multiple and sometimes redundant mechanisms for drug transport, metabolism and targets. Deciphering the pathways is the first step towards understanding how genetic variation could potentially contribute to the changes in functionality of critical components of the drug pathway. In addition, it also provides crucial insights into the molecular mechanisms of drug-drug and drug-environment interactions and how genetic variations could modulate this phenomenon. A comprehensive outline of anti-arrhythmic drugs and their drug pathways are summarized in Figure 1.

The major area that would require focused attention in the immediate future is towards standardized efforts to collate pharmacogenomics data and evidence to enable meta-analysis, while at the same time be able to keep pace with the latest avalanche of evidence brought to light by high throughput genomics studies including Genome-wide associations studies (GWAS). Community led approaches like PharmGKB (www.pharmgkb.org) and crowd-sourcing approaches like OpenPgx (www.openpgx.org) are the possible way forward, and both approaches should be organized complementary to each other. Apart from the data, the second focus area is computational tools and resources that can handle the high-throughput datasets. The availability of genome-wide scans as direct-to-consumer services has also provided an immense opportunity and challenge at the same time. With adequate computational tools and resources for interpretation of the data, this has the potential to lower the cost, while at the same time, widen the general acceptability of genetic testing. No healthcare intervention system is complete without adequate education and empowerment of the medical and paramedical professionals and the patients. For the success of widespread acceptability and application of pharmacogenomics testing for cardiac arrhythmias, appropriate focus and emphasis on awareness and healthcare education is essential.
These efforts should be complemented and supplemented by both systematic ways of collecting data and being able to analyze it to unravel emerging phenomena. This would necessitate creation of effective systems for systematic collection and sharing of clinical data, treatment protocols and outcome measures. This includes setting up of registries, which follow standard protocols, metadata and modes of data exchange. This also requires setting up collaborative and shared data resources and analytical approaches. In summary, seamless exchange of ideas, resources and knowhow between research laboratories and clinicians is essential to realize the dream of making pharmacogenomics based personalized medicine a reality.

Figure 1: Overview of the drug pathways for anti-arrhythmic drugs. The coloured drugs and edges represent drugs while the metabolizing enzymes are marked as solid circles. The transporters and targets are represented as solid triangles and rhomboids respectively.

Modeling a disease process or pathway is the next critical step in understanding the molecular mechanisms and the genetic architecture of disease processes. Animal models such as rodents and mammals have been used successfully for modeling cardiac arrhythmias. Recently advances include the application of newer model systems for understanding pharmacogenomics principles. Model organisms like zebrafish, which are easy to maintain and study, have been shown to be useful in modeling pharmacological principles and potential mode of action of many therapeutic agents.
Acknowledgements

The authors thank Dr. Shantanu Sengupta and Dr Mohd Faruq for reviewing the manuscript. Authors also thank Mr Jatin Talwar for discussions and visualization of data and Dr Yasha Hasija for comments and discussions. The authors acknowledge the OpenPGx (www.openpgx.org) consortium and community for data annotation from literature. This study is funded by CSIR India.

References

1. Domanski, Michael J.: The epidemiology of atrial fibrillation. Coronary Artery Disease 1995, 6:95-100.

2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.

3. Zheng, Z.J., Croft, J.B., Giles, W.H. & Mensah GA.: Sudden cardiac death in the United States, 1989 to 1998. Circulation 104, 2158–2163.

4. Naik, N., Yadav, R., Juneja, R.: Epidemiology of arrhythmias in India: How do we obtain reliable data? Current Science 2009, 97:411-16.

5. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM.: Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011, 25(6):473-90.

6. Crivellente, F: The Sooner the Better: utilising biomarkers to eliminate drug candidates with cardiotoxicity in preclinical development. Available at: http://www.ddw-online.com/s/summer-2011/p148216/the-sooner-the-better:-utilising-biomarkers-to-eliminate-drug-candidates-with-cardiotoxicity-in-preclinical-development.html

7. Lokhandwala Y.: Arrhythmia care in India-poised for the big leap. Indian Pacing Electrophysiol J. 2002, 2(1):1.

8. Singh, H and Gupta, G and Gupta, MS and Anand, JS and Aggarwal, R and Verma, RP.: A 24 hour holter study in asymptomatic elderly Indians. JIAM 2003, 4(4): 308-14.

9. Arulmani R, Rajendran SD, Suresh B.: Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2008 Feb;65(2):210-6.

10. Harkcom WT, Abbott GW.: Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking. Expert Rev Cardiovasc Ther. 2010, 8:1161-73.

11. Roden DM, Kannankeri PJ, Darbar D.: Arrhythmia pharmacogenomics: methodological considerations. Curr Pharm Des. 2009, 15:3734-41.

12. Clancy CE, Zhu ZI, Rudy Y.: Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol. 2007, 292:H66-75.

13. Darbar D, Roden DM.: Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother. 2006, 7:1583-90.

14. Shuraih M, Ai T, Vatta M, Sohma Y, Merkle EM, Taylor E, Li Z, Xi Y, Razavi M, Towbin JA, Cheng J. : A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. J Cardiovasc Electrophysiol. 2007 Apr;18(4):434-40. Epub 2007 Jan 10.
15. Barajas-Martínez HM, Hu D, Cordeiro JM, Wu Y, Kovacs RJ, Meltser H, Kui H, Elena B, Brugada R, Antzelevitch C, Dumaine R.: Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008, 103:396-404.

16. Sheets PL, Jackson JO 2nd, Waxman SG, Dib-Hajj SD, Cummins TR.: A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J Physiol. 2007, 581:1019-31.

17. Fan Z, George AL Jr, Kyle JW, Makielski JC.: Two human paramyotonia congenita mutations have opposite effects on lidocaine block of Na+ channels expressed in a mammalian cell line. J Physiol. 1996, 496:275-86.

18. Kesavan R, Narayan SK, Adithan C.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010, 66:689-96.

19. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT.: Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010, 11:349-56.

20. Azzato EM, Chen RA, Wacholder S, Chanock SJ, Klebanoff MA, Caporaso NE.: Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenet Genomics. 2010, 20:58-63.

21. Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG.: CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther. 2010, 332:599-611.

22. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L.: Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics. 2008, 18:989-98.

23. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V.: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008, 49:2087-91.

24. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007, 48:1015-8.

25. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH.: A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006, 16:721-6.

26. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005, 102:5507-12.

27. Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JJ, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA.: CACNA1C gene polymorphisms,
28. Kurnik D, Cunningham AJ, Sofowora GG, Kohli U, Li C, Friedman EA, Muszkat M, Menon UB, Wood AJ, Stein CM.: GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009, 10:1581-7.

29. Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, Xie HG, Harris PA, Williams SM, Nair UB, Wood AJ, Stein CM.: Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics. 2008, 18:895-902.

30. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaehe TY, Pepine CJ, Johnson JA; INVEST Investigators.: Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008, 84:715-21.

31. Iaccarino G, Izzo R, Trimarco V, Cipolletta E, Lanni F, Sorriento D, Iovino GL, Rozza F, De Luca N, Priante O, Di Renzo G, Trimarco B.: Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clin Pharmacol Ther. 2006, 80:633-45.

32. Liljedahl U, Lind L, Kurland L, Berglund L, Kahan T, Syvänen AC.: Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment. BMC Cardiovasc Disord. 2004, 4:16.

33. Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.: Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol. 2004, 27:347-50.

34. Hallberg P, Karlsson J, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.: Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol. 2004, 27:287-90.

35. Filigheddu F, Reid JE, Troffà C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, Glorioso N.: Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J. 2004, 4:154-60.

36. Hallberg P, Lind L, Billberger K, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.: Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol. 2004, 27:169-73.

37. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L.: Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens. 2004, 17:8-13.

38. Diez J, Laviades C, Orbe J, Zalba G, López B, González A, Mayor G, Páramo JA, Beloqui O.: The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens. 2003, 21:2085-92.

39. Hallberg P, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP,
Nyström F, Liljedahl U, Syvänen AC, Melhus H.: Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. BMC Cardiovasc Disord. 2003, 3:11.

40. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, Prasad HC, Byrne DW, Nair UB, Wood AJ, Stein CM.: A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther. 2003, 73:366-71.

41. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens. 2002, 15:389-93.

42. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.: Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2002, 20:657-63.

43. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ.: The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond). 2000, 99:233-8.

44. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L; Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial.: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 2001, 19:1783-7.

45. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P.: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens. 1996, 14:259-62.

46. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P.: Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010, 24:49-60.

47. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW 2nd.: Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009, 54:432-44.

48. Troncoso R, Moraga F, Chiong M, Roldán J, Bravo R, Valenzuela R, Díaz-Araya G, del Campo A, Sanhueza C, Rodriguez A, Vukasovic JL, Mellado R, Greig D, Castro PF, Lavandero S.: Gln(27)->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol. 2009, 104:374-8.

49. Sehnert AJ, Daniels SE, Elashoff M, Elashoff DA, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggert SB, Anderson JL, Kraus WE.: Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008, 52:644-51.

50. Chen L, Meyers D, Javorsky G, Burstow D, Lolekha P, Lucas M, Semmler AB, Savarimuthu SM, Fong KM, Yang IA, Atherton J, Galbraith AJ, Parsonage WA, Molenaar P.: Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics. 2007, 17:941-9.
51. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB.: Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003, 9:1300-5.

52. Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, Nyegaard M, Børglum AD, Stender S, Kober L, Torp-Pedersen C, Poulsen HE.: Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol. 2011, 71:556-65.

53. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D.: Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003, 13:379-82.

54. Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, Nievergelt CM, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS; AASK Study Investigators.: G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009, 22:332-8.

55. Jin SK, Chung HJ, Chung MW, Kim JI, Kang JH, Woo SW, Bang S, Lee SH, Lee HJ, Roh J.: Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther. 2008, 33:567-73.

56. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH.: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009, 85:45-50.

57. Lobmeyer MT, Gong Y, Terra SG, Beitselshees AL, Langae TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA.: Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007, 17:277-82.

58. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH.: beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006, 80:23-32.

59. Beitselshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA.: Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J. 2006, 6:174-8.

60. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA.: Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005, 15:227-34.

61. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH.: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003, 74:372-9.

62. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, Balmforth AJ; MERIT-HF Study Group.: An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003, 5:463-8.
63. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF.: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003, 74:44-52.

64. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM.: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002, 105:1943-8.

65. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J, Cordes JS, Zhou J.: Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol. 2004, 37:1031-9.

66. Niu Y, Gong Y, Langae TY, Davis HM, Elewa H, Beitzelshees AL, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA.: Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENetic Substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010, 3:548-55.

67. van Noord C, Aarnoudse AJ, Eijgelsheim M, Strukkenboom MC, Straus SM, Hofman A, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH.: Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics. 2009, 19:260-6.

68. Beitzelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langae TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; INVEST Investigators.: KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007, 17:719-29.

69. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN.: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007, 28:959-67.

70. Bartnicka L, Kurzawski M, Drozdzik A, Plonska-Gosciniak E, Górnik W, Drozdzik M.: Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol Rep. 2007, 59:323-9.

71. Chowbay B, Li H, David M, Cheung YB, Lee EJ.: Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol. 2005, 60:159-71.

72. Morita N, Yasumori T, Nakayama K.: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol. 2003, 65:1843-52.

73. Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K.: MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res. 2003, 20:552-6.

74. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003, 58:809-12.
76. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001, 70:189-99.

77. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-8.